Delphi advisor to AddLife in the acquisition of advanced surgery business

Delphi has advised AddLife AB (publ) (“AddLife”) and its subsidiary AddLife Development AB in the acquisition of all shares in DACH Medical Group Holding AG (“DACH”).

AddLife is an independent distributor within Life Science that offer high-quality products, services and advice to both the private and public sectors. The corporation develops and acquires profitable companies in selected niche areas in the segments diagnostics, biomedical research and laboratory analysis and medtech. In 2019, AddLife had a turnover of SEK 3,479 million.

DACH is the parent company in a group with operations in the advanced surgery product area. The business is conducted in Austria, Switzerland and Germany in a segment in which AddLife is already established as a supplier in the Nordic and Central European markets. DACH Medical Group markets and sells both own brands and products from leading suppliers in advanced surgery such as laparoscopy and endoscopy, urology, thoracic medicine and gynaecology. The products are sold to customers in both public and privately funded care in Austria, Switzerland and Germany. The acquisition is a good complement to existing operations in advanced surgery at AddLife. DACH’s operates with own salesforce in all three countries and the business has 23 employees with a total net sales of approximately EUR 14 million.

Delphi has been lead counsel in the acquisition and cooperated with the law firm Schoenherr in Austria.

Delphi’s team mainly consisted of Fredrik Mörner as responsible partner with assistance from several other lawyers at Delphi.